Anjaneya Chimalakonda

1.5k total citations
28 papers, 453 citations indexed

About

Anjaneya Chimalakonda is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Anjaneya Chimalakonda has authored 28 papers receiving a total of 453 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 10 papers in Molecular Biology and 7 papers in Immunology. Recurrent topics in Anjaneya Chimalakonda's work include Drug Transport and Resistance Mechanisms (6 papers), Biosimilars and Bioanalytical Methods (5 papers) and Cytokine Signaling Pathways and Interactions (5 papers). Anjaneya Chimalakonda is often cited by papers focused on Drug Transport and Resistance Mechanisms (6 papers), Biosimilars and Bioanalytical Methods (5 papers) and Cytokine Signaling Pathways and Interactions (5 papers). Anjaneya Chimalakonda collaborates with scholars based in United States, Germany and Sweden. Anjaneya Chimalakonda's co-authors include Reza Mehvar, Ragini Vuppugalla, Ihab Girgis, John Throup, Tatyana Zvyaga, A. David Rodrigues, Cliff Chen, Zheng Yang, Andrew J. Wagner and Shu‐Ying Chang and has published in prestigious journals such as Analytical Chemistry, Annals of the Rheumatic Diseases and Pharmaceutical Research.

In The Last Decade

Anjaneya Chimalakonda

28 papers receiving 441 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Anjaneya Chimalakonda United States 11 115 109 107 89 55 28 453
Kourosh Parivar United States 9 133 1.2× 111 1.0× 179 1.7× 85 1.0× 29 0.5× 21 649
Susan Grange Switzerland 11 90 0.8× 111 1.0× 189 1.8× 170 1.9× 29 0.5× 17 611
Kosalaram Goteti United States 13 134 1.2× 142 1.3× 91 0.9× 60 0.7× 33 0.6× 32 489
Shunji Matsuki Japan 14 115 1.0× 79 0.7× 190 1.8× 121 1.4× 33 0.6× 40 681
Olivier Luttringer Switzerland 8 88 0.8× 36 0.3× 89 0.8× 107 1.2× 35 0.6× 13 330
Anshu Marathe United States 11 183 1.6× 72 0.7× 203 1.9× 46 0.5× 26 0.5× 22 559
Jenny Zheng United States 13 143 1.2× 49 0.4× 315 2.9× 96 1.1× 46 0.8× 26 634
Parnian Zia‐Amirhosseini United States 11 142 1.2× 176 1.6× 112 1.0× 111 1.2× 111 2.0× 18 747
Million Arefayene United States 8 175 1.5× 96 0.9× 162 1.5× 107 1.2× 23 0.4× 13 451
Tarundeep Kakkar United States 10 252 2.2× 113 1.0× 94 0.9× 66 0.7× 30 0.5× 18 538

Countries citing papers authored by Anjaneya Chimalakonda

Since Specialization
Citations

This map shows the geographic impact of Anjaneya Chimalakonda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anjaneya Chimalakonda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anjaneya Chimalakonda more than expected).

Fields of papers citing papers by Anjaneya Chimalakonda

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anjaneya Chimalakonda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anjaneya Chimalakonda. The network helps show where Anjaneya Chimalakonda may publish in the future.

Co-authorship network of co-authors of Anjaneya Chimalakonda

This figure shows the co-authorship network connecting the top 25 collaborators of Anjaneya Chimalakonda. A scholar is included among the top collaborators of Anjaneya Chimalakonda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anjaneya Chimalakonda. Anjaneya Chimalakonda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Dockens, Randy, et al.. (2023). Pharmacokinetics and Safety of the Tyrosine Kinase 2 Inhibitor Deucravacitinib in Healthy Chinese Subjects. Dermatology and Therapy. 13(12). 3153–3164. 3 indexed citations
2.
Chimalakonda, Anjaneya, James R. Burke, Lihong Cheng, et al.. (2021). Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors. Dermatology and Therapy. 11(5). 1763–1776. 88 indexed citations
3.
Khandelwal, Purnima, et al.. (2021). Pharmacokinetics of 40 kDa Polyethylene glycol (PEG) in mice, rats, cynomolgus monkeys and predicted pharmacokinetics in humans. European Journal of Pharmaceutical Sciences. 165. 105928–105928. 3 indexed citations
4.
Chimalakonda, Anjaneya, et al.. (2019). P638 BMS-986165, an oral selective tyrosine kinase 2 (TYK2) inhibitor, does not affect the pharmacokinetics of methotrexate in healthy subjects. Journal of Crohn s and Colitis. 13(Supplement_1). S437–S438. 3 indexed citations
5.
Khandelwal, Purnima, Lisa Zhang, Anjaneya Chimalakonda, et al.. (2019). Pharmacokinetics of 40 kDa PEG in rodents using high-field NMR spectroscopy. Journal of Pharmaceutical and Biomedical Analysis. 171. 30–34. 8 indexed citations
6.
Zhu, Yongxin, Celia D’Arienzo, Zhen Lou, et al.. (2016). LC–MS/MS Multiplexed Assay for The Quantitation of A Therapeutic Protein BMS-986089 and The Target Protein Myostatin. Bioanalysis. 8(3). 193–204. 22 indexed citations
7.
Madireddi, Malavi T., Daniel Kukral, Anjaneya Chimalakonda, et al.. (2016). BMS-986089 is a high affinity anti-myostatin adnectin that increases muscle volume in three preclinical species. Neuromuscular Disorders. 26. S94–S95. 9 indexed citations
8.
Finlay, Heather J., James A. Johnson, John Lloyd, et al.. (2016). Discovery of 5-Phenyl-N-(pyridin-2-ylmethyl)-2-(pyrimidin-5-yl)quinazolin-4-amine as a PotentIKurInhibitor. ACS Medicinal Chemistry Letters. 7(9). 831–834. 11 indexed citations
9.
Chimalakonda, Anjaneya, et al.. (2015). Development and characterization of a free therapeutic ligand binding assay with assistance from kinetics modeling. Journal of Immunological Methods. 419. 18–24. 3 indexed citations
10.
Chimalakonda, Anjaneya, Rajbharan Yadav, & Punit Marathe. (2013). Factors Influencing Magnitude and Duration of Target Inhibition Following Antibody Therapy: Implications in Drug Discovery and Development. The AAPS Journal. 15(3). 717–727. 10 indexed citations
11.
Zvyaga, Tatyana, Shu‐Ying Chang, Cliff Chen, et al.. (2012). Evaluation of Six Proton Pump Inhibitors As Inhibitors of Various Human Cytochromes P450: Focus on Cytochrome P450 2C19. Drug Metabolism and Disposition. 40(9). 1698–1711. 99 indexed citations
12.
13.
Chimalakonda, Anjaneya & Reza Mehvar. (2007). Effects of Methylprednisolone and Its Liver-Targeted Dextran Prodrug on Ischemia–Reperfusion Injury in a Rat Liver Transplantation Model. Pharmaceutical Research. 24(12). 2231–2238. 10 indexed citations
14.
Chimalakonda, Anjaneya, Donald L. Montgomery, Jon A. Weidanz, et al.. (2006). Attenuation of Acute Rejection in a Rat Liver Transplantation Model by a Liver-Targeted Dextran Prodrug of Methylprednisolone. Transplantation. 81(5). 678–685. 15 indexed citations
15.
16.
Mehvar, Reza & Anjaneya Chimalakonda. (2004). Hepatic disposition of cyclosporine A in isolated perfused rat livers.. PubMed. 7(1). 47–54. 4 indexed citations
17.
Vuppugalla, Ragini, Rakhi B. Shah, Anjaneya Chimalakonda, Charles Fisher, & Reza Mehvar. (2003). Microsomal Cytochrome P450 Levels and Activities of Isolated Rat Livers Perfused with Albumin. Pharmaceutical Research. 20(1). 81–88. 8 indexed citations
18.
Chimalakonda, Anjaneya & Reza Mehvar. (2003). Attenuation of Kupffer Cell Activation in Cold-Preserved Livers After Pretreatment of Rats with Methylprednisolone or Its Macromolecular Prodrug. Pharmaceutical Research. 20(7). 1001–1008. 6 indexed citations
19.
Chimalakonda, Anjaneya & Reza Mehvar. (2003). Dextran-Methylprednisolone Succinate as a Prodrug of Methylprednisolone: Local Immunosuppressive Effects in Liver After Systemic Administration to Rats. Pharmaceutical Research. 20(2). 198–204. 11 indexed citations
20.
Chimalakonda, Anjaneya, Rakhi B. Shah, & Reza Mehvar. (2002). High-performance liquid chromatographic analysis of cyclosporin A in rat blood and liver using a commercially available internal standard. Journal of Chromatography B. 772(1). 107–114. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kourosh Parivar Breakdown of academic impact, for papers by Susan Grange Breakdown of academic impact, for papers by Kosalaram Goteti Breakdown of academic impact, for papers by Shunji Matsuki Breakdown of academic impact, for papers by Olivier Luttringer Breakdown of academic impact, for papers by Anshu Marathe Breakdown of academic impact, for papers by Jenny Zheng Breakdown of academic impact, for papers by Parnian Zia‐Amirhosseini Breakdown of academic impact, for papers by Million Arefayene Breakdown of academic impact, for papers by Tarundeep Kakkar
Rankless by CCL
2026